Alimera Sciences, Inc., and its subsidiaries (we, Alimera or the Company), is a
biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals. We are presently
focused on diseases affecting the back of the eye, or retina, because we believe
these diseases are not well treated with current therapies and represent a
significant market opportunity.
Our only commercial product is ILUVIEN�, which has received marketing
authorization in Austria, the United Kingdom, Portugal, France, Germany and
Spain, and has been recommended for marketing authorization in Italy, for the
treatment of vision impairment associated with chronic diabetic macular edema
(DME) considered insufficiently responsive to available therapies. DME is a
disease of the retina that affects individuals with diabetes and can lead to
severe vision loss and blindness.